MYO9A

Across TCGA pan-cancer cohorts, MYO9A mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MYO9A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MYO9A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYO9A is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where MYO9A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO9A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−0.674	<.001	9	view →
LUAD	Male	III,IV	−0.465	<.001	9	view →
CCRCC	Male	All	+0.250	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MYO9A–LSCC

Open the LSCC breakdown →